Eli Lilly's stock is being closely watched by investors ahead of its earnings report. The company has made significant investments, including a recent acquisition and a $7 billion spend on cancer treatment, which may impact its stock performance in 2026. However, there is uncertainty about the stock's trajectory, with some outlets reporting outpacing market gains and others noting the stock has sunk despite market gains.